GlobeNewswire·Nov 9, 2026, 4:05 PM ET

Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Phase 3 ACCOMPLISH-1 & ACCOMPLISH-2 trials for aleniglipron are enrolling, with topline data expected in 2H 2028.
Additional aleniglipron data from body composition, type 2 diabetes, & SWITCH studies is expected in Q4 2026.
Phase 1 SAD data for ACCG-2671 showed a ~6-day half-life & no serious adverse events, while MAD dosing is underway with topline data expected in 1H 2027.
Cash, cash equivalents, & short-term investments totaled $1.2 billion as of September 30, 2026, funding operations through 2028.
The Phase 3 ACCOMPLISH program initiated in August 2026, with ACCOMPLISH-1 enrolling up to 3,600 adults & ACCOMPLISH-2 enrolling up to 1,100 adults with T2DM.
72-week ACCESS OLE data showed up to 16.2% mean weight reduction at the highest dose with no plateau & discontinuation rates under 5%.
Structure Therapeutics will present two aleniglipron posters at ObesityWeek 2026 on November 15, 2026.
ACCG-2671 MAD trial evaluates safety, tolerability, PK, & combination with injectable GLP-1 receptor agonists.
Phase 1 trial for ACCG-3535 is planned to initiate in Q4 2026, with a combination amylin/GLP-1 trial expected in 2027.
R&D expenses for Q3 2026 were $134.6 million, compared to $59.0 million in the prior year period.
G&A expenses for Q3 2026 were $21.8 million, compared to $14.8 million in the prior year period.
Net loss for Q3 2026 was $144.8 million, compared to $65.7 million in the prior year period.

Company: Structure Therapeutics Inc.
Keywords: Nasdaq:GPCR, Structure Therapeutics Inc., ALENIGLIPRON, AMYLIN, GLP-1, SMALL MOLECULE, GPCR